With biopharma IPOs surging, GoodRx guns for $750M raise
The 2020 biopharma IPO wave has picked up a company or two that doesn’t look like your traditional drug developer. In June, most notably, Royalty Pharma, a company that has made a tidy business over the years buying up future royalties for approved and experimental drugs, nabbed the largest biotech — if you can a call it a biotech — IPO in history at $2.2 billion.
Then on Friday, after a week dominated by small-cap offerings like Virios Therapeutics, GoodRx announced they too would try to go public. And although they don’t quite have Pablo Legorreta-like ambitions, the consumer prescription drug platform and drug price watchdog is reportedly still shooting well above Moderna: $750 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.